Company: MYSEW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044159
Chunk: 117

Company: Myseum, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 117
---
ion of stock-based stock option and common stock expense of $155,054, offset by
changes in operating assets and liabilities primarily consisting of an increase in prepaid expenses of $15,959, and an increase in accounts
payable and accrued expenses of $69,092.

Net cash flow used in operating activities for
the three months ended March 31, 2024 primarily reflected a net loss of $1,561,807 adjusted for the add-back (reduction) of non-cash items
consisting of depreciation and amortization of $5,782, amortization of right of use assets of $17,123, accretion of stock-based stock
option and common stock expense of $59,018, a non-cash gain from deconsolidation of variable interest entities of $(107), and foreign
currency exchange loss of $12,965, offset by changes in operating assets and liabilities primarily consisting of an increase in prepaid
expenses of $52,659, an increase in accounts payable and accrued expenses of $61,794, and a decrease in operating lease liabilities of
$19,376.

Cash Flows from Investing Activities

Net cash used by investing activities amounted
to $2,905,332 and $648,447 for the three months ended March 31, 2025 and 2024, respectively.

During the three months ended March 31, 2025,
we purchased short-term investments of $4,314,310 and received gross proceeds from the sale of short-term investments of $1,481,603. Additionally,
we capitalized internal-use software of $72,625.

During the three months ended March 31, 2024,
we purchased short-term investments of $3,337,115 and received gross proceeds from the sale of short-term investments of $2,688,668.

Cash Flows from Financing Activities

Net cash provided by financing activities totaled
$4,379,500 and $1,420,773 for the three months ended March 31, 2025 and 2024, respectively.

During the three months ended March 31, 2025,
we received $4,532,000 from the sale of common stock, net, and paid deferred offering costs of $152,500.

During the three months ended March 31, 2024,
we received $559,251 from the sale of common stock, net, and received $861,522 from the sale of pre-funded warrants.

27 

Off-Balance Sheet